huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1, open-label study to evaluate the feasibility, safety and preliminary efficacy of huCART19-IL18-eDHFR cells administered in patients with relapsed or refractory follicular lymphoma. This study will be initiated as a single arm study (Treatment Arm A), which will evaluate the use of huCART19-IL18-eDHFR cells without prior lymphodepletion. In this Treatment Arm A, all subjects will receive a single flat dose of 7x10\[6\] huCART19-IL18-eDHFR cells (Dose Level 1; DL1). Additional treatment arms may also be introduced in the future, via subsequent amendment(s). Co-expression of eDHFR within huCART19-IL18 cells will allow the trafficking of the transduced CAR T cells to be visualized by PET/CT imaging using an investigational radiolabeled imaging agent \[18F\]Fluoropropyl-Trimethoprim (also known as \[18F\]FP-TMP). The feasibility of using \[18F\]FP-TMP PET/CT imaging to detect and measure the eDHFR-expressing CAR T cells will be investigated, as well as its ability to provide insight into CAR T cell pharmacokinetics, biodistribution, and persistence.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Zdiagnozowany chłoniak pęcherzykowy (stopień 1-3A)
- •Choroba powróciła lub nie reaguje na co najmniej 2 poprzednie leczenia systemowe
- •Potwierdzone wirusowe białko CD19 na komórkach nowotworu
- •Zmiany nowotworu widoczne w badaniach w ciągu ostatnich 12 tygodni
- •Dobre funkcjonowanie narządów (nerki, wątroba, serce, płuca)
- •Brak poważnych infekcji lub zapalenia wątroby
- •Podpisana zgoda na uczestnictwo w badaniu
✗ Disqualifies
- •Aktywna infekcja wirusem hepatitis B lub C
- •Niekontrolowana infekcja w organizmie
- •Poważne problemy z sercem (klasa III/IV)
- •Arytmia (nieregularne bicie serca) niestabilna pomimo leczenia
- •Historia przeszczepienia szpiku z poważnymi powikłaniami
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Pennsylvania
Philadelphia, United States
Trial contact
Abramson Cancer Center Clinical Trials Service
Stephen Schuster, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.